

designated at the following address: HCFA, Office of Financial and Human Resources, Management Analysis and Planning Staff, Attention: John Rudolph, Room C2-25-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: February 10, 1997.

Edwin J. Glatzel,

*Director, Management Analysis and Planning Staff, Office of Financial and Human Resources.*

[FR Doc. 97-3985 Filed 2-18-97; 8:45 am]

BILLING CODE 4120-03-M

## Public Health Service

### Title: FNB Workshop on Folate, Vitamin B-12, and Choline

**AGENCY:** Office of Disease Prevention and Health Promotion, HHS.

**ACTION:** Food and Nutrition Board Workshop on Folate, B-12, and Choline; notice of meeting and request for information.

**SUMMARY:** The Food and Nutrition Board (FNB), Institute of Medicine, National Academy of Sciences, under the auspices of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, will hold an open workshop to address the nutrients folate, vitamin B-12, and choline.

**DATES:** The open meeting will be held from 12:30 until 5:30 p.m. E.S.T. on March 3, 1997, and from 8 a.m. until 12:30 p.m. E.S.T. on March 4, 1997, at the Jefferson Auditorium, U.S. Department of Agriculture South Building, 14th and Independence Avenue, S.W., Washington, D.C. The meeting is open to the public.

**FOR FURTHER INFORMATION, CONTACT:** Diane Johnson, Program Assistant, Food and Nutrition Board, 2101 Constitution Avenue, NW., Washington, D.C. 20418, (202) 334-1312, or send an e-mail to FNB@NAS.EDU.

**SUPPLEMENTARY INFORMATION:** Speakers have been invited to present evidence bearing on requirements and adverse effects, if any, of high levels of intake of folate, vitamin B-12, and choline. Information presented will be considered by the committee in its development of Dietary Reference Intakes for these nutrients. Interested individuals and organizations are encouraged to provide written scientific information for the committee's use. Those wishing to be considered for a brief oral presentation should submit an abstract with references to FNB, 2101 Constitution Ave., NW, Washington, DC 20418, by February 24, 1997. The study

for which this meeting is being held is supported by the Department of Health and Human Services (Office of Disease Prevention and Health Promotion, Office of Public Health and Science; the Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; and the Office of Dietary Supplements, National Institutes of Health).

The meeting is open to the public; however seating is limited. If you will require a sign language interpreter, please call Diane Johnson (202) 334-1312 by 4:30 p.m. E.S.T. on February 21, 1997.

Dated: February 6, 1997.

Claude Earl Fox,

*Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion), Department of Health and Human Services.*

[FR Doc. 97-4040 Filed 2-18-97; 8:45 am]

BILLING CODE 4160-17-M

## Office of Public Health and Science; Notice of Partnership Initiative

Pursuant to Title XVII of the Public Health Service Act, notice is hereby given that the Office of Disease Prevention and Health Promotion, Office of Public Health and Science, is seeking partnerships with non-Federal organizations to promote, distribute and encourage the implementation of "Put Prevention into Practice." "Put Prevention into Practice" is a system-based approach to implementing the recommendations of the United States Preventive Services Task Force, targeting patients, clinicians, and medical offices. The goal is to increase the impact of "Put Prevention into Practice" by forming partnerships with private sector organizations. These cooperative efforts are intended to bring the resources of several partners to bear on the implementation of clinical preventive services guidelines and on the efforts to increase the delivery of appropriate clinical preventive services, efforts that are too complex for any one organization to handle alone. Organizations with particular experience, expertise or interest in the development, marketing and distribution of prevention-related materials to the general public, professional organizations and managed care organizations will be well-aligned with current and planned initiatives of "Put Prevention into Practice" activities.

Note: Partnerships between ODPHP and outside organizations will be formalized

through Memorandum of Agreements and will not involve grants or contracts.

Date of Effectiveness: February 19, 1997.

For more information, please contact Rika Maeshiro, M.D., M.P.H., Senior Clinical Affairs Advisor, Office of Disease Prevention and Health Promotion, Office of Public Health and Science, at 202-690-7943.

Dated: February 10, 1997.

Claude Earl Fox,

*Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion).*

[FR Doc. 97-4039 Filed 2-18-97; 8:45 am]

BILLING CODE 4160-17-M

## Substance Abuse and Mental Health Services Administration

### Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Drug Testing Advisory Board of the Center for Substance Abuse Prevention in April 1997.

The Drug Testing Advisory Board (DTAB) is having a 3-day scientific meeting to discuss drug testing alternative specimens and technologies as they apply to workplace drug testing programs. The entire meeting is open to the public; however, attendance by the public will be limited to space available. The first two days will consist of presentations on the principles and criteria of workplace drug testing program requirements and industry representatives discussing alternative specimens/technologies (urine, hair, saliva, sweat, and non-instrument based on-site tests). The presentations will be focused on the following areas for each alternative specimen/technology: specimen collection and chain of custody, initial test reagents and procedures, confirmatory test procedures, internal quality control program, reporting test results, interpreting test results, and an external quality assurance program. On the third day, the DTAB will review the presentations, identify areas of concern, and make recommendations concerning those specimens/technologies for workplace drug testing.

Interested persons may present information or views, orally or in writing, on these issues pending before the Board. Those desiring to make formal presentations should notify the contact person before March 7. A coordinator for each alternative specimen/technology will select the presenters. The presenters who will discuss the underlying principles and